Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $43.0 million.

  • Syndax Pharmaceuticals' Share-based Compensation rose 1.24% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 24.30%. This contributed to the annual value of $43.0 million for FY2024, which is 39.01% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Share-based Compensation stood at $43.0 million for FY2024, which was up 39.01% from $31.0 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Share-based Compensation ranged from a high of $43.0 million in FY2024 and a low of $9.1 million during FY2020.
  • Over the past 3 years, Syndax Pharmaceuticals' median Share-based Compensation value was $31.0 million (recorded in 2023), while the average stood at $30.0 million.
  • Data for Syndax Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 93.21% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Share-based Compensation stood at $9.1 million in 2020, then surged by 47.04% to $13.3 million in 2021, then increased by 20.29% to $16.0 million in 2022, then spiked by 93.21% to $31.0 million in 2023, then soared by 39.01% to $43.0 million in 2024.